Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment [Un trial randomizzato, di fase 2b, in aperto, sulla somministrazione di JX-594 (Virus vaccinico per GM-CSF e TK disattivato) piu' terapia di supporto ottimale vs. Terapia di supporto ottimale in pazienti affetti da carcinoma epatocellulare avanzato in cui il trattamento con sorafenib e' fallito]

Next Previous
Trial Profile

A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment [Un trial randomizzato, di fase 2b, in aperto, sulla somministrazione di JX-594 (Virus vaccinico per GM-CSF e TK disattivato) piu' terapia di supporto ottimale vs. Terapia di supporto ottimale in pazienti affetti da carcinoma epatocellulare avanzato in cui il trattamento con sorafenib e' fallito]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
  • 10 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
  • 12 Sep 2013 A decision on the further development of Pexa-Vec in liver cancer will be announced in the fourth quarter of 2013, according to a Transgene media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top